Document is current

Article History

Accepted: 14 March 2025

First Online: 17 April 2025

Competing interests

: C.N.H. discloses research support from Celgene (BMS), Constellation, GSK and Novartis; and honoraria/consulting fees from Abbvie, AOP, BMS, CTI, IMAGO, Incyte, Novartis, Galacteo, Geron, GSK, Janssen, Keros, MSD, SOBI and Morphosys. T.B. discloses research support ftom GSK and AOP; and honoraria/consulting fees from AOP, Italfarmaco, Ionis and Novartis. P.B. discloses research support from Incyte, BMS, CTI, Morphosys, Sumitomo, Karyopharm, Kartos, Telios, Ionis, Disc, Ajax, Geron, Janssen, Blueprint and Cogent; and honoraria/consulting fees from Incyte, BMS, CTI, GSK, Abbvie, Morphosys, Sumitomo, Karyopharm, Ionis, Disc, Geron, Keros, Pharma Essentia, Jubilant, Morphic, Novartis, Blueprint, Ono, Raythera and Cogent. J.-J.K. discloses honoraria/consulting fees from Novartis, GSK, Abbvie, BMS, Incyte, AOP Health and PharmaEssentia. J.M. discloses research funding from Incyte, Novartis, BMS, CTI/SOBI, Abbvie, Geron, Kartos, Karyopharm AJAX, Italfarmaco Spa, Disc and PharmaEssentia; and consulting fees from Incyte, Novartis, BMS, Geron, Karyopharm, Kartos, GSK, PharmaEssentia, Italfarmaco Spa, Abbvie, Roche, Merck, Pfizer, Galecto, MorphoSys, Disc, Keros and Sumitomo. M.F.M. discloses research support from BMS and AOP; and honorarium/consulting fees from Novartis, GSK, Incyte, BMS and AOP. R.M. discloses research support from Abbvie, Blueprint, BMS, CTI, Genentech, Incyte, Morphosys and Sierra; and honoraria/consulting fees from Abbvie, Blueprint, BMS, CTI, Genentech, Geron, GSK, Incyte, Novartis, Sierra, Sierra Oncology and Telios. A.M.V. discloses honoraria/consulting fees from Incyte, Novartis, AOP, Italfarmaco, BMS, GSK, Abbvie, Blueprint and Ionis Disc.